

RESULTS OF 2026 AGM

Nexalis Therapeutics Limited (ASX: NX1) ("**NX1**", "**Nexalis**" or "**the Company**") advises its 2026 Annual General Meeting (**Meeting**) was held today, 29 May 2026, commencing at 4pm AEST.

Six (6) resolutions were put to members at the Meeting, each of which were voted on a poll. At the commencement of the Meeting, the Chair withdrew resolutions 3 and 6, which pertained to Dr Ron Wise who recently retired as a director. In addition, resolution 2, the contingent spill resolution, was not required to be put to the meeting as less than 25% of valid votes cast on resolution 1, the adoption of the remuneration report, were cast against that resolution.

In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), details of the resolutions, proxies received in respect of the resolutions and poll results are set out in the attached summary.

The Board thanks shareholders for their support.

Authorised for release by the Board of Directors.

For further information:

www.nexalitherapeutics.com

James Barrie, Company Secretary

T: +61 3 9070 1221

E: investors@nexalitherapeutics.com

Investor relations

Matthew Wright

NWR Communications

M: 0451 896 420

E: matt@nwrcommunications.com.au

ABOUT NEXALIS THERAPEUTICS LTD (ASX: NX1)

Nexalis Therapeutics Ltd is an Australian Clinical Stage Drug Development Company that is developing rapid onset therapies to address unmet medical needs in pain management and mental health sectors. The Company is currently focused on the development of IRX-211 to treat Breakthrough Cancer Pain ('**BTcP**'), IRX-616a to treat Panic Disorder ('**PD**') and SRX-25 for the treatment of Treatment-Resistant Depression ('**TRD**').

The overarching goal is to pursue U.S. FDA approval and registration using rapid and cost-effective regulatory pathways, such as 505(b)(2).

There is a significant economic opportunity for NX1 and the Company's shareholders, with the clinical indications under investigation carefully selected in consultation with regulatory authorities. Bringing new approved medications to market will address critical gaps whereby there's currently mismatched treatment options that can carry dependency concerns.

CONTACT US

NEXALIS THERAPEUTICS

T: +61 3 9070 1221 | E: investors@nexalitherapeutics.com | W: <https://www.nexalitherapeutics.com>



In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to the resolutions put to members at the meeting, which were **decided on a Poll**.

	Resolution	Proxy Votes					Poll			Result	
		For	Against	Open	Exclusions	Abstain	Total	For	Against	Abstain	Carried / Not Carried
Resolution 1	ADOPTION OF REMUNERATION REPORT	14,612,541	-	-	1,326,881	19,949,999	14,612,541	34,358,540	204,000	-	Carried
		100.00%	0.00%	0.00%			99.41%	0.59%			
Resolution 2	SPILL RESOLUTION (CONTINGENT)	WITHDRAWN									
Resolution 3	RE-ELECTION OF DIRECTOR – DR RON WISE	WITHDRAWN									
Resolution 4	APPROVAL OF 7.1A MANDATE	4,426,881	31,462,540	-	-	-	35,889,421	12,571,454	31,462,540	-	Not Carried
		12.33%	87.67%	0.00%			28.55%	71.45%			
Resolution 5	APPROVAL OF ISSUE OF SHARE RIGHTS TO A DIRECTOR IN LIEU OF FEES – SEAN WILLIAMS	35,105,332	-	-	784,089	-	35,105,332	35,105,332	-	-	Carried
		100.00%	0.00%	0.00%			100.00%	0.00%			
Resolution 6	APPROVAL OF ISSUE OF SHARE RIGHTS TO A DIRECTOR IN LIEU OF FEES – DR RON WISE	WITHDRAWN									
Resolution 7	APPROVAL OF ISSUE OF SHARE RIGHTS TO A DIRECTOR IN LIEU OF FEES – ANTHONY FITZGERALD	35,105,332	-	-	784,089	-	35,105,332	35,105,332	-	-	Carried
		100.00%	0.00%	0.00%			100.00%	0.00%			
Resolution 8	RATIFICATION OF PRIOR ISSUE OF BALANCE OF TRANCHE 1 PLACEMENT SECURITIES	35,685,421	204,000	-	-	-	35,889,421	35,885,252	204,000	7,944,742	Carried
		99.43%	0.57%	0.00%			99.43%	0.57%			
Resolution 9	RATIFICATION OF PRIOR ISSUE OF SHARES	35,685,421	204,000	-	-	-	35,889,421	43,829,994	204,000	-	Carried
		99.43%	0.57%	0.00%			99.54%	0.46%			